Ensign Peak Advisors Inc Has $1.17 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Ensign Peak Advisors Inc lessened its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 8.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,850 shares of the company’s stock after selling 6,500 shares during the period. Ensign Peak Advisors Inc’s holdings in Teva Pharmaceutical Industries were worth $1,171,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. New Age Alpha Advisors LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter worth $43,000. Sound Income Strategies LLC lifted its stake in Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $74,000. Brooklyn Investment Group grew its stake in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after purchasing an additional 4,014 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after acquiring an additional 767 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 2.4%

NYSE TEVA opened at $26.94 on Friday. The stock’s 50-day simple moving average is $21.60 and its two-hundred day simple moving average is $18.80. The company has a market capitalization of $30.90 billion, a price-to-earnings ratio of -168.38, a PEG ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $26.96. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares in the company, valued at $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.49% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TEVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and a consensus target price of $25.86.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.